NUTROPIN HGH: HGH HORMONE PRODUCT
Written by , Article reviewed and edited by Dr. Fine M.D.
Published on September 4th, 2019
Free HGH Consultation. Call : 1-800-996-9664
Hormone Replacement Therapy
Nutropin is produced
by Genentech using recombinant DNA technology and has the same amino
acid sequence as human growth hormone produced naturally in the
human body. Recombinant growth hormone was cloned by Genentech scientists
ABOUT ADULT GROWTH HORMONE
Growth hormone (hGH or GH) doesn't just contribute to physical growth
in children. Adults need GH, too. In adults, GH is essential to
the maintenance of healthy body composition and metabolism. When
an adults body is unable to produce enough GH, he or she is said
to have adult GH deficiency (AGHD).
Some people with adult
growth hormone (hGH or GH) deficiency were not GH-deficient as children.
These people are said to have adult-onset GH deficiency.
The usual cause of adult-onset
GH deficiency is damage to the pituitary gland, which is responsible
for secreting GH. This damage is most commonly caused by one or
more tumors in and around the pituitary. Such a tumor may compress
the gland, or the damage may occur when the tumor is removed. The
pituitary gland may also be damaged by infection, blood vessel disease,
severe head injury, or radiation treatment for tumors of the head
or neck. .
Growth hormone deficiency, GHD, is a pituitary disorder resulting
in short stature and other physical ailments. GHD occurs when the
production of growth hormone, secreted by the pituitary gland, is
disrupted. Since growth hormone plays a critical role in stimulating
body growth and development, and is involved in the production of
muscle protein and in the breakdown of fats, a decrease in the hormone
affects numerous body processes.
Turner syndrome affects
approximately one in 2,500 female, live births. Turner syndrome
is a chromosomal disorder that affects females exclusively and is
characterized, in part, by short stature and ovarian dysfunction.
It is caused by the absence of all or part of one of the X chromosomes.
Chronic renal insufficiency, CRI, affects about 3,000 children in
the United States. It manifests through a gradual and progressive
loss of the ability of the kidneys to excrete wastes, concentrate
urine, and conserve electrolytes. Kidney transplants can help a
child start growing normally again, but most children do not make
up the growth lost prior to transplantation.
Growth hormone should not be initiated to treat patients with acute
critical illness due to complications following open heart or abdominal
surgery, multiple accidental trauma or to patients having acute
Growth Hormone should
not be used for growth promotion in pediatric patients with closed
Growth Hormone should not be used in patients with active neoplasia.
Growth Hormone therapy should be discontinued if evidence of neoplasia
develops. Patients with a history of an intracranial lesion should
be examined frequently for progression or recurrence of the lesion.
(IH) with papilledema, visual changes, headache, nausea, and/or
vomiting has been reported in a small number of patients treated
with Growth Hormone. Funduscopic examination of patients is recommended
at the initiation and periodically during Growth Hormone therapy.
Patients with CRI or Turner's Syndrome may be at increased risk
for development of IH.
Growth Hormone may reduce
insulin sensitivity, particularly in obese individuals, patients
should be observed for evidence of glucose intolerance. For patients
with diabetes mellitus, the insulin dose may require adjustment
when Growth Hormone therapy is instituted.
Experience with prolonged
Growth Hormone treatment in adults is limited.
Adverse events frequently reported in adult patients were edema
(41%), arthralgias and other joint disorders (27%). Thirty-five
percent of childhood-onset adult Growth Hormone deficient subjects
treated with Growth Hormone 0.025 mg/kg/day for 2 years had supraphysiologic
levels of insulin-like growth factor-I (IGF-I) at some time during
the study, which may carry unknown risks. During therapy, dosage
should be decreased if required by the occurrence of side effects
or excessive IGF-I levels.
Patients being treated
with Growth Hormone (GH) should be informed of the potential benefits
and risks associated with Growth Hormone therapy.
For additional product
Information visit: www.nutropin.com
Number of words: 657
HORMONE AND TESTOSTERONE MEDICAL LINKS
HORMONE DECLINE CHARTS